Nicotine Addiction Clinical Trial
Official title:
Effect of Nicotine on Acquisition and Extinction of a Conditioned Place Preference in a Virtual Reality Environment
In this between-subjects, placebo controlled, double-blind study, the investigators will examine the effects of low oral doses of nicotine on the learning and extinction of a conditioned place preference acquired in a virtual reality environment by healthy human subjects. Physiological and subjective responses to the drug will also be monitored.
External cues and contexts contribute to the development of smoking and the use of other drugs, and drugs themselves can alter the value of conditioned cues. Interestingly, nicotine increases the acquisition of new learning, and has been considered as a "cognitive enhancer". Nicotine also prolongs responding when responding is no longer rewarded, during extinction. Although many studies have examined the effects of drugs on learning (acquisition) and unlearning (extinction) in laboratory animals, few have investigated drug effects on learning in humans. Recently, novel procedures have been developed to study conditioning in humans, pairing initially neutral places with food, money or drugs. The investigators will use one of these procedures, a virtual place conditioning procedure, to study how nicotine affects the acquisition and extinction of conditioned behaviors in humans. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02643914 -
Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings
|
N/A | |
Completed |
NCT02153749 -
Effects of Brief Training on Craving Regulation
|
N/A | |
Recruiting |
NCT05530577 -
Effects of Semaglutide on Nicotine Intake
|
Phase 2 | |
Withdrawn |
NCT05440721 -
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
|
N/A | |
Completed |
NCT03694327 -
Innovative Digital Therapeutic for Smoking Cessation
|
N/A | |
Completed |
NCT01944423 -
Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine
|
Early Phase 1 | |
Completed |
NCT01704573 -
Nicotinic Receptor Levels After Stopping Smoking
|
N/A | |
Active, not recruiting |
NCT01015170 -
STOP Study: Effectiveness of Zyban in a Clinical Population
|
Phase 4 | |
Completed |
NCT03281629 -
Circuitry-Guided Smoking Cessation in Schizophrenia
|
N/A | |
Recruiting |
NCT06291584 -
Effects of Exercises on Functional Capacity
|
N/A | |
Completed |
NCT02624284 -
tDCS Effects on Resisting Smoking: Dose Ranging Study
|
N/A | |
Active, not recruiting |
NCT02837510 -
Neural Mechanisms Associated With Risk of Smoking Relapse
|
N/A | |
Completed |
NCT02656745 -
Clinical Trial of Smoking Cessation Mobile Phone Program
|
N/A | |
Completed |
NCT01062932 -
Investigation of Cycloserine as a Smoking Cessation Treatment
|
Phase 1 | |
Completed |
NCT03069482 -
Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness
|
Phase 1 | |
Completed |
NCT02870218 -
Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use
|
Phase 2 | |
Terminated |
NCT01756053 -
Effects of ABT-089 on Smoking Abstinence Symptoms and Reward
|
Phase 2 | |
Completed |
NCT01252966 -
Cognitive Training for Nicotine Dependence
|
N/A | |
Active, not recruiting |
NCT04946825 -
Quit Smoking Study for People Who Use E-Cigarettes
|
Phase 2 | |
Recruiting |
NCT05434429 -
Mobile Health for Problematic Behaviors and Substance Use
|
N/A |